Rosiglitazone treatment and cardiovascular disease in the <scp>V</scp> eterans <scp>A</scp> ffairs <scp>D</scp> iabetes Trial

Abstract

In older patients with T2D the use of rosiglitazone was associated with decreased risk of the primary CV composite outcome and CV death. Rosiglitazone use did not lead to a higher risk of MI.